Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Multi-center, Randomized, Heparin-controlled Dose-finding Trial to Evaluate the Efficacy and Safety of Rivaroxaban, a Direct Factor Xa Inhibitor, on the Background of Standard Dual Antiplatelet Therapy to Support Elective Percutaneous Coronary Intervention

NCT01442792 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT01442792
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01442792 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Multi-center, Randomized, Heparin-controlled Dose-finding Trial to Evaluate the Efficacy and Safety of Rivaroxaban, a Direct Factor Xa Inhibitor, on the Background of Standard Dual Antiplatelet Therapy to Support Elective Percutaneous Coronary Intervention
Lead sponsor
Bayer
Phase
Phase 2
Overall status
Completed
Start date
October 12, 2011
Completion date
March 4, 2013
Enrollment
108 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

cardiovascular disease, coronary artery disease